RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:98839

Intravascular large B-cell lymphoma

low confidenceDisorder

Also known as: Angioendotheliomatosis proliferans systemisata · Angiotropic large cell lymphoma · Intravascular lymphomatosis · Malignant angioendotheliomatosis · Tappeiner-Pfleger disease

Publications

2,537

Trials

8

Interventional, condition-specific

Researchers

1,109

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Intravascular large B-cell lymphoma (IVLBCL) is a very rare form of diffuse large B-cell lymphoma characterized by the selective growth of lymphoma cells within the lumina of small blood vessels (especially the capillaries) that most often presents with a wide range of clinical manifestations (as potentially any tissue can be involved), with patients from Western countries more frequently manifesting with neurological and cutaneous symptoms while patients from Asian countries more frequently displaying and thrombocytopenia. IVLBCL is characterized by an absence of lymphadenopathy, an aggressive clinical course and a poor prognosis.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

angioendotheliomatosis proliferans systemisata · angiotropic large cell lymphoma · angiotropic lymphoma · intravascular B-cell lymphoma · intravascular large B-cell lymphoma · intravascular lymphomatosis · malignant angioendotheliomatosis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    2,537 matched papers (1,264 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    8 matched on ClinicalTrials.gov (2 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

2,537

2,537 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

2,537 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

1,264 in the last 10 years · low confidence

Phrase hits: 2,537 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,109

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang X9 papers · 2026

    Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

    Papers in Europe PMC
  2. 02
    Zhang W8 papers · 2026

    Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.

    Papers in Europe PMC
  3. 03
    Li Y6 papers · 2026

    Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Shandong, 264000, China.

    Papers in Europe PMC
  4. 04
    Wang W6 papers · 2026

    Department of Hematology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.

    Papers in Europe PMC
  5. 05
    Zhang Y6 papers · 2026

    Department of Hematology, The First Hospital of Jilin University, ChangChun, Jilin, China.

    Papers in Europe PMC
  6. 06
    Li Z5 papers · 2026

    Department of Hematology, The First Hospital of Jilin University, ChangChun, Jilin, China.

    Papers in Europe PMC
  7. 07
    Matsue K5 papers · 2026

    Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan.

    Papers in Europe PMC
  8. 08
    Chen Y4 papers · 2026

    Department of Pathology, The Affiliated Hospital of Qingdao University , ,

    Papers in Europe PMC
  9. 09
    Li J4 papers · 2025

    Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, People's Republic of China.

    Papers in Europe PMC
  10. 10
    Liu X4 papers · 2026

    Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, People's Republic of China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

8

interventional trials for this specific condition

8 interventional trials matched this specific condition name; 2 currently recruiting in our sample.

Data as of 27 July 2026

8 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 90.6th percentile).

low confidence · 90.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

8 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Intravascular large B-cell lymphoma" OR "Angioendotheliomatosis proliferans systemisata" OR "Angiotropic large cell lymphoma" OR "Intravascular lymphomatosis" OR "Malignant angioendotheliomatosis" OR "Tappeiner-Pfleger disease" OR "angiotropic lymphoma" OR "intravascular B-cell lymphoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Intravascular large B-cell lymphoma" OR "Angioendotheliomatosis proliferans systemisata" OR "Angiotropic large cell lymphoma" OR "Intravascular lymphomatosis" OR "Malignant angioendotheliomatosis" OR "Tappeiner-Pfleger disease" OR "angiotropic lymphoma" OR "intravascular B-cell lymphoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 8 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (2537) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T05:33:13.024Z